C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525318-75-00

Enrollment

120

Registered

2026-09-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight or Obesity

Brief summary

Body weight percent change from baseline (CFB) at Week 72.

Detailed description

Body weight (kg) CFB at Week 72., Waist circumference (cm) CFB at Week 72., SBP (mmHg) CFB at Week 72., IWQoL-Lite-CT Physical Function composite score CFB at Week 72.

Interventions

DRUGPF-08653944

DRUGPlacebo to match PF-08653944

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Body weight percent change from baseline (CFB) at Week 72.	—

Secondary

Measure	Time frame
Body weight (kg) CFB at Week 72., Waist circumference (cm) CFB at Week 72., SBP (mmHg) CFB at Week 72., IWQoL-Lite-CT Physical Function composite score CFB at Week 72.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 12, 2026